News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AntiOp Partners With Reckitt Benckiser Pharmaceuticals Inc. To Develop Nasally Administered Treatment For Opioid Overdose


5/21/2014 9:24:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Ky.--(BUSINESS WIRE)--AntiOp, Inc., a Kentucky company founded by Dr. Daniel Wermeling, has signed an agreement with Reckitt Benckiser Pharmaceuticals, Inc. to accelerate production and worldwide marketing of intranasal naloxone, a drug designed to treat opioid overdose.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES